WO2004000312A3 - Arzneimittel zur behandlung von eine inhibition oder aktivitätsverminderung von ph-wert-regulierenden bikarbonat-transporter-proteinen erfordernden erkrangungen - Google Patents

Arzneimittel zur behandlung von eine inhibition oder aktivitätsverminderung von ph-wert-regulierenden bikarbonat-transporter-proteinen erfordernden erkrangungen Download PDF

Info

Publication number
WO2004000312A3
WO2004000312A3 PCT/EP2003/006319 EP0306319W WO2004000312A3 WO 2004000312 A3 WO2004000312 A3 WO 2004000312A3 EP 0306319 W EP0306319 W EP 0306319W WO 2004000312 A3 WO2004000312 A3 WO 2004000312A3
Authority
WO
WIPO (PCT)
Prior art keywords
diseases
activity
reduction
value
medicament
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2003/006319
Other languages
English (en)
French (fr)
Other versions
WO2004000312A2 (de
Inventor
Heinz Rupp
Bernd Eisele
Dieter Ziegler
Bodo Jaeger
Bernhard Maisch
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Abbott Products GmbH
Original Assignee
Solvay Pharmaceuticals GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Solvay Pharmaceuticals GmbH filed Critical Solvay Pharmaceuticals GmbH
Priority to AU2003257418A priority Critical patent/AU2003257418A1/en
Priority to EP03760622A priority patent/EP1517688A2/de
Priority to CA002487541A priority patent/CA2487541A1/en
Publication of WO2004000312A2 publication Critical patent/WO2004000312A2/de
Publication of WO2004000312A3 publication Critical patent/WO2004000312A3/de
Priority to US11/013,326 priority patent/US7309706B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/421—1,3-Oxazoles, e.g. pemoline, trimethadione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Es wird die Verwendung von Selektiven Imidazolin Rezeptor Agonisten, insbesondere von Moxonidin, Rilmenidine, LNP-509, S-23515, PMS-812, PMS-847 und BU-98008, und deren physiologisch verträglichen Säureadditionssalzen zur Herstellung von pharmazeutischen Zubereitungen zur Behandlung und/oder Prophylaxe von funktionellen Störungen und/oder Erkrankungen in grösseren Säugetieren oder Menschen, die eine Inhibition oder Verminderung der Aktivität von den intrazellulären pH-Wert regulierenden und zur Superfamilie der Bikarbonat-Transporter gehörenden Proteinen erfordern, insbesondere von Krankheitsbildern der Knochen, die durch ein unerwünschtes Mass an Knochenresorption bedingt sind, insbesondere Osteoporose, von Erkrankungen des gastrointestinalen Traktes, insbesondere Magengeschwüre, und von neuronalen und/oder neuropsychiatrischen Erkrankungen, die mit einer pathologisch veränderten, vorzugsweise einer gesteigerten neuronalen Aktivität zusammenhängen, vorzugsweise Depression, Alzheimer'sche Erkrankung, Essstörungen und Schizophrenie, beschrieben.
PCT/EP2003/006319 2002-06-19 2003-06-16 Arzneimittel zur behandlung von eine inhibition oder aktivitätsverminderung von ph-wert-regulierenden bikarbonat-transporter-proteinen erfordernden erkrangungen Ceased WO2004000312A2 (de)

Priority Applications (4)

Application Number Priority Date Filing Date Title
AU2003257418A AU2003257418A1 (en) 2002-06-19 2003-06-16 Medicament for the treatment of diseases requiring inhibition or a reduction in the activity of ph value-regulating bicarbonate transporter proteins
EP03760622A EP1517688A2 (de) 2002-06-19 2003-06-16 Arzneimittel zur behandlung von eine inhibition oder aktivitätsverminderung von ph-wert-regulierenden bikarbonat-transporter-proteinen erfordernden erkrangungen
CA002487541A CA2487541A1 (en) 2002-06-19 2003-06-16 Medicament for the treatment of diseases requiring inhibition or a reduction in the activity of ph value-regulating bicarbonate transporter proteins
US11/013,326 US7309706B2 (en) 2002-06-19 2004-12-17 Method for the treatment of diseases requiring inhibition or a reduction in the activity of pH value-regulating bicarbonate transporter proteins

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP02013387 2002-06-19
EP02013387.2 2002-06-19

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US11/013,326 Continuation US7309706B2 (en) 2002-06-19 2004-12-17 Method for the treatment of diseases requiring inhibition or a reduction in the activity of pH value-regulating bicarbonate transporter proteins

Publications (2)

Publication Number Publication Date
WO2004000312A2 WO2004000312A2 (de) 2003-12-31
WO2004000312A3 true WO2004000312A3 (de) 2004-02-19

Family

ID=29797127

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2003/006319 Ceased WO2004000312A2 (de) 2002-06-19 2003-06-16 Arzneimittel zur behandlung von eine inhibition oder aktivitätsverminderung von ph-wert-regulierenden bikarbonat-transporter-proteinen erfordernden erkrangungen

Country Status (6)

Country Link
US (1) US7309706B2 (de)
EP (1) EP1517688A2 (de)
AU (1) AU2003257418A1 (de)
CA (1) CA2487541A1 (de)
PL (1) PL372695A1 (de)
WO (1) WO2004000312A2 (de)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2612854B1 (de) * 2005-10-25 2015-04-29 Shionogi&Co., Ltd. Aminothiazolidin- und Aminotetrahydrothiazepin-Derivate als BACE 1-Inhibitoren
TW200902526A (en) * 2007-04-24 2009-01-16 Shionogi & Amp Co Ltd Aminodihydrothiazin derivative substituted with a cyclic group
WO2008133273A1 (ja) * 2007-04-24 2008-11-06 Shionogi & Co., Ltd. アルツハイマー症治療用医薬組成物
WO2009151098A1 (ja) * 2008-06-13 2009-12-17 塩野義製薬株式会社 βセクレターゼ阻害作用を有する含硫黄複素環誘導体
US12246013B2 (en) 2008-08-01 2025-03-11 Eye Therapies Llc Vasoconstriction compositions and methods of use
ES2518418T3 (es) 2008-08-01 2014-11-05 Eye Therapies Llc Composiciones de vasoconstricción y métodos de uso
US8952011B2 (en) 2008-08-01 2015-02-10 Eye Therapies Llc Compositions and methods for the treatment of nasal conditions
US20100203165A1 (en) * 2008-08-01 2010-08-12 Gerald Horn Compositions and methods for treatment of disorders or conditions of the eye
JPWO2010047372A1 (ja) * 2008-10-22 2012-03-22 塩野義製薬株式会社 Ｂａｃｅ１阻害活性を有する２−アミノピリミジン−４−オンおよび２−アミノピリジン誘導体
US8987270B2 (en) 2009-07-27 2015-03-24 Eye Therapies Llc Formulations of selective alpha-2 agonists and methods of use thereof
UA110467C2 (uk) 2009-12-11 2016-01-12 Шионогі Енд Ко., Лтд. Похідні оксазину
WO2011075621A1 (en) * 2009-12-17 2011-06-23 Alpha Synergy Development, Inc. Compositions and methods for ophthalmic delivery of nasal decongestants
CN103261199A (zh) 2010-10-29 2013-08-21 盐野义制药株式会社 萘啶衍生物
EP2634188A4 (de) 2010-10-29 2014-05-07 Shionogi & Co Kondensiertes aminodihydropyrimidinderivat
US8445526B2 (en) 2011-02-03 2013-05-21 Glaucoma & Nasal Therapies Llc Compositions and methods for treatment of glaucoma
WO2012147763A1 (ja) 2011-04-26 2012-11-01 塩野義製薬株式会社 オキサジン誘導体およびそれを含有するｂａｃｅ１阻害剤
EP2912035A4 (de) 2012-10-24 2016-06-15 Shionogi & Co Dihydrooxazin- oder oxazepinderivate mit bace1-hemmender wirkung
US8999938B2 (en) 2013-06-21 2015-04-07 Gnt Llc Ophthalmic lipophilic drug delivery vehicle formulations
KR20160042039A (ko) 2013-08-09 2016-04-18 알데릭스, 인코포레이티드 인산염 수송을 억제하기 위한 화합물 및 방법
CN110358723A (zh) * 2019-05-08 2019-10-22 广州医科大学附属第二医院 一种成年小鼠心脏成纤维细胞的培养方法
EP3735974A1 (de) * 2019-05-10 2020-11-11 Rottapharm Biotech S.r.l. Verwendung von 2-phenyl-6-(1h-imidazol-1-yl)chinazolin zur behandlung von neurodegenerativen erkrankungen, insbesondere morbus alzheimer
WO2021158059A1 (ko) * 2020-02-07 2021-08-12 건국대학교 글로컬산학협력단 릴메니딘 화합물을 유효성분으로 포함하는 취약 x 증후군 또는 관련 발달 장애 치료용 조성물
KR20250145285A (ko) * 2024-03-28 2025-10-13 건국대학교 글로컬산학협력단 릴메니딘을 포함하는 정서장애의 예방, 개선 또는 치료용 조성물

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0846688A1 (de) * 1996-12-04 1998-06-10 Adir Et Compagnie Neue Imidazolinderivate mit Imidazolin-Rezeptor Affinität
WO2000002878A1 (en) * 1998-07-11 2000-01-20 University Of Bristol Compounds having activity at imidazoline receptors
EP1038526A1 (de) * 1999-03-15 2000-09-27 Solvay Pharmaceuticals GmbH Behandlung von funktionellen Störungen der unteren Darmwege und einhergehenden visceralen Schmerzen mit Moxonidin

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4102890A (en) * 1972-12-28 1978-07-25 Science-Union Et Cie, Societe Francaise De Recherche Medicale 2-Amino oxazolines and process for making the same
GB1453703A (en) 1972-12-28 1976-10-27 Science Union & Cie Substituted cyclopropylmethylamines processes for their preparation and pharmaceutical compositions containing them
DE2849537C2 (de) 1978-11-15 1983-03-17 Beiersdorf Ag, 2000 Hamburg Substituierte 5-(2-Imidazolin-2-yl)-aminopyrimidine, Verfahren zu deren Herstellung und diese enthaltende Arzneimittel
US4323570A (en) * 1978-11-15 1982-04-06 Beiersdorf Aktiengesellschaft Substituted aminopyrimidines
DE3739779A1 (de) * 1987-11-24 1989-06-08 Beiersdorf Ag Pharmazeutische praeparate
FR2707984B1 (fr) 1993-07-23 1995-09-01 Adir Nouvelles pipérazines substituées, leur procédé de préparation et les compositions les contenant.
CA2190870A1 (en) * 1994-05-27 1995-12-07 George D. Hartman Compounds for inhibiting osteoclast-mediated bone resorption
DE4423177A1 (de) * 1994-07-01 1996-01-04 Kali Chemie Pharma Gmbh Antihyperglykämisch wirksame Arzneimittel
FR2726558B1 (fr) 1994-11-03 1996-12-06 Adir Nouvelles 5-(aryloxymethyl) oxazolines, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
FR2733685B1 (fr) * 1995-05-05 1997-05-30 Adir Utilisation des derives du benzopyrane pour l'obtention de compositions pharmaceutiques destinees au traitement des pathologies liees a l'echangeur c1-/hc03-, na+ independant
US5804587A (en) * 1995-06-29 1998-09-08 The Procter & Gamble Company 6-(2-imidazolinylamino) quinolines useful as alpha-2 adrenoceptor agonists
CA2182851A1 (en) * 1995-08-15 1997-02-16 August Masaru Watanabe Method for treating substance abuse withdrawal
DE19629817A1 (de) 1996-07-24 1998-01-29 Hoechst Ag Neue Imino-Derivate als Inhibitoren der Knochenresorption und Vitronectinrezeptor-Antagonisten
DE69830114D1 (de) * 1997-09-16 2005-06-16 Solvay Pharm Gmbh Analgetische Zusammensetzung welche Moxonidine und ein Opioid-Analgetika enthält
US6054461A (en) * 1997-09-16 2000-04-25 Solvay Pharmaceuticals Gmbh Treatment of neuropathic pain
US6117879A (en) * 1997-09-16 2000-09-12 Solvay Pharmaceuticals Gmbh Methods of using moxonidine to inhibit nociceptive pain
US6777394B1 (en) * 1998-07-15 2004-08-17 George D. Prell Methods and compositions for regulating imidazoline receptors
US6475752B1 (en) * 1999-07-30 2002-11-05 Incyte Genomics, Inc. Mammalian imidazoline receptor
DE19938823A1 (de) * 1999-08-19 2001-02-22 Boehringer Ingelheim Pharma Medikamentöse Behandlung des Restless Leg Syndroms
FR2801051B1 (fr) 1999-11-17 2001-12-14 Adir Nouveaux composes aminopyrroline, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
GB9929216D0 (en) 1999-12-11 2000-02-02 Univ Bristol Isoquinoline and Quinoline Containing substances
JP2004512830A (ja) * 2000-08-18 2004-04-30 ブリストル−マイヤーズ　スクイブ　カンパニー 新規イミダゾリンレセプター相同体
DE10052524A1 (de) * 2000-10-23 2002-04-25 Beko Technologies Gmbh Filter zum Abscheiden von Fremdstoffen aus einem Gasstrom
IL147921A0 (en) * 2002-01-31 2002-08-14 Abdulrazik Mohammad A method for treating central nervous system disorders by ocular dosing

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0846688A1 (de) * 1996-12-04 1998-06-10 Adir Et Compagnie Neue Imidazolinderivate mit Imidazolin-Rezeptor Affinität
WO2000002878A1 (en) * 1998-07-11 2000-01-20 University Of Bristol Compounds having activity at imidazoline receptors
EP1038526A1 (de) * 1999-03-15 2000-09-27 Solvay Pharmaceuticals GmbH Behandlung von funktionellen Störungen der unteren Darmwege und einhergehenden visceralen Schmerzen mit Moxonidin

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
GLAVIN G B ET AL: "EFFECTS OF THE SELECTIVE I1 IMIDAZOLINE RECEPTOR AGONIST, MOXONIDINE, ON GASTRIC SECRETION AND GASTRIC MUCOSAL INJURY IN RATS", BRITISH JOURNAL OF PHARMACOLOGY, BASINGSTOKE, HANTS, GB, vol. 114, no. 4, 1995, pages 751 - 754, XP000916660, ISSN: 0007-1188 *
NUTT D J ET AL: "FUNCTIONAL STUDIES OF SPECIFIC IMIDAZOLINE-2 RECEPTOR LIGANDS", ANNALS OF THE NEW YORK ACADEMY OF SCIENCES, NEW YORK ACADEMY OF SCIENCES, NEW YORK, NY, US, vol. 736, 1995, pages 125 - 139, XP002038401, ISSN: 0077-8923 *
POISSON D ET AL: "Neuroprotective effects of rilmenidine on neuronal and glial cell injuries induced by hypoxia.", CELL BIOLOGY AND TOXICOLOGY, vol. 14, no. 2, March 1998 (1998-03-01), 6th Congress of the Society of Cellular Pharmacotoxicology and the French Society of Genetic Toxicology;Paris, France; March 6-7, 1997, pages 153, XP009000595, ISSN: 0742-2091 *
REIS DONALD J ET AL: "Protection of focal ischemic infarction by rilmenidine in the animal: Evidence that interactions with central imidazoline receptors may be neuroprotective.", AMERICAN JOURNAL OF CARDIOLOGY, vol. 74, no. 13, 1994, pages 25A - 30A, XP009000589, ISSN: 0002-9149 *
SCHLATTER EBERHARD ET AL: "Moxonidine inhibits Na+/H+ exchange in proximal tubule cells and cortical collecting duct.", KIDNEY INTERNATIONAL, vol. 52, no. 2, 1997, pages 454 - 459, XP009000588, ISSN: 0085-2538 *

Also Published As

Publication number Publication date
EP1517688A2 (de) 2005-03-30
US7309706B2 (en) 2007-12-18
US20050165080A1 (en) 2005-07-28
AU2003257418A1 (en) 2004-01-06
WO2004000312A2 (de) 2003-12-31
PL372695A1 (en) 2005-07-25
CA2487541A1 (en) 2003-12-31

Similar Documents

Publication Publication Date Title
NO20053077L (no) Terapeutiske formuleringer for behandling av beta-amyloid-relaterte sykdommer.
IT1276783B1 (it) Formulazioni farmaceutiche e dietetiche per la profilassi e la cura di affezioni gastrointestinali
MX9400287A (es) Procedimiento para la preparacion de un medicamento util para el tratamiento de la enfermedad de parkinson
WO2003099771A3 (en) Diaryl urea derivatives useful for the treatment of protein kinase dependent diseases
MX9307882A (es) Aplicacion de la lamotrigina para la preparacion de medicamentos para el tratamiento de lesiones neurologicas ligadas a traumatismos.
GB0211649D0 (en) Organic compounds
WO2000064441A3 (en) Compound for use as a medicament for treatment of disorders involving bronchocontraction
PT1427436E (pt) Utilização de apoproteínas do soro do leite na profilaxia ou tratamento de infecção microbiana ou viral
PL372695A1 (en) Medicament for the treatment of diseases requiring inhibition or a reduction in the activity of ph value-regulating bicarbonate transporter proteins
EP1228758A4 (de) Prohylaktische und therapeutische mittel für entzündliche darmerkrankungen
WO2004056768A3 (en) Use of substituted 2,5-diamidoindoles for the treatment of urological diseases
WO2003009835A3 (en) Novel use of 2-[5-(4-fluorophenyl)-3-pyridylmethylaminomethyl]-chromane and its physiologically acceptable salts
PT1387836E (pt) Derivados de ftalazina com actividade de inibição de angiogénese
WO2000076500A3 (en) Compound for use as a medicament for treatment of disorders involving bronchocontraction
EP3508201A3 (de) Glycin als dietätische zugabe zur verwendung in der behandlung von hautproblemen, die aus zugrundeliegenden kollagenstörungen resultieren
WO2005087255A3 (en) Method of optimizing treatment with interferon-tau
ATE331523T1 (de) Statin-therapie zur verbesserung der aufrechterhaltung der kognitiven funktion
WO2004034062A3 (en) Use of cap-1 for the therapy of asthma
BR9917605A (pt) Composição substituta de plasma
DE60004093D1 (de) Pharmazeutische zusammensetzung welche riluzol und gabapentin enthält zur behandung von motoneuronalen krankheiten
AU7230894A (en) Use of efaxoran and its derivatives for the production of drugs for treating neurodegenerative diseases
SI1497250T1 (sl) Derivati hiperforina, njihova uporaba in formulacije, ki jih vsebujejo
WO2004039978A3 (de) Humanes chondroosteomodulin (tig2), herstellung und verwendung zur behandlung oder diagnose von knochen- und knorpelerkrankungen, fettsucht sowie entzündlichen erkrankungen und hauterkrankungen
Brooks et al. Histoplasmosis: update 1998
US20060074077A1 (en) Pharmaceutical composition for the treatment of athetoid movement

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2487541

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 372695

Country of ref document: PL

Ref document number: 11013326

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 2003257418

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2003760622

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2003760622

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Ref document number: JP

WWW Wipo information: withdrawn in national office

Ref document number: 2003760622

Country of ref document: EP